Asia Pacific Human Liver Models Market

The APAC human liver models market is expected to grow from US$ 33,191.56 thousand in 2021 to US$ 76,341.40 thousand by 2028; it is estimated to grow at a CAGR of 12.6% from 2021 to 2028. China, Japan, India, South Korea, and Australia are major economies in APAC. Increasing focus on drug discovery activities is expected to surge the market growth. Before a new drug is tested in a clinical study, the main phase analysis of pharmacodynamics and pharmacokinetics is carried out using animal models and two-dimensional (2D) in vitro models. The It takes 1215 years and US$ 35 billion to bring a single drug to market. The increasing demand for new and advanced drugs is driving the general pace of drug discovery and discovery. As a result, a high number of clinical studies are being conducted to invent and commercialize new drugs. Even after the market launch (phase IV), there are still many drug withdrawals for toxicological reasons. About 1830% of these withdrawals are due to hepatotoxic effects, which shows that the liver is the most common target for adverse drug reactions (ADRs). The liver plays a crucial role in drug metabolism, body homeostasis, digestion, and toxic substance excretion. In the case of the liver, the simplest models for drug discovery are isolated subcellular fractions, such as microsomes, which contain drug-metabolizing enzymes (DMEs) or isolated mitochondria. To enable high sensitivity and specificity, the cell-based models are required to replicate higher order drug processes [i.e., biotransformation, transport kinetics, secondary metabolite formation, and drug interactions (DDIs)]. Human liver models are used to assess the metabolism and toxicity of chemical compounds and drugs, and to assess drug candidates in cancer research and genetic studies. The significant increase in clinical trials is expected to fuel demand for advanced medical technologies, including organoid models, thereby driving the APAC market growth. The APAC biopharmaceutical industry has been disturbed for a few months in 2020 during the outbreak of COVID-19. The COVID-19 pandemic interrupted clinical trials due to restrictions imposed to control the spread of infection. However, with the rising demand for products to treat the COVID-19 infection, the biopharmaceutical and pharmaceutical companies in India and China continued to focus on research activities. For instance, in February 2020, Vir Biotechnology (US) partnered with WuXi Biologics (China) to develop human monoclonal antibodies to treat COVID-19 infections. This partnership involves clinical development, manufacturing, and commercialization, and WuXi Biologics will be responsible for process and formulation development and early production for clinical development. Moreover, companies in the region have put core activities on hold to focus on the COVID-19 vaccine development. For instance, in March 2020, biotech CRO Novotech (Australia) partnered with Komipharm International (South Korea) for clinical trials of Panaphix as a potential treatment for COVID-19. The recent restrictions imposed by many countries in response to the COVID-19 outbreak have impacted ongoing clinical research. With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the APAC human liver models market. The APAC human liver models market is expected to grow at a good CAGR during the forecast period. APAC Human Liver Models Market Revenue and Forecast to 2028 (US$ Thousand) APAC Human Liver Models Market Segmentation APAC Human Liver Models Market By Type - Liver Organoids - Liver-on-a-chip - 2D Models - 3D Bioprinting - Others APAC Human Liver Models Market By Application - Drug Discovery - Educational - Others APAC Human Liver Models Market By End User - Pharmaceutical and Biotechnology Companies - Research Institutes - Others APAC Human Liver Models Market, by Country - Japan - China - India - South Korea - Australia - Rest of APAC APAC Human Liver Models Market -Companies Mentioned - BioIVT - CELLINK - CYFUSE BIOMEDICAL K.K. - Emulate, Inc. - InSphero - Kerafast - MIMETAS BV - THERMO FISHER SCIENTIFIC INC.

Asia Pacific Human Liver Models Strategic Insights

Strategic insights for the Asia Pacific Human Liver Models provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Asia Pacific Human Liver Models Report Scope

Asia Pacific Human Liver Models Regional Insights

The geographic scope of the Asia Pacific Human Liver Models refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.